We are live on ! Find out more
CARM

Carisma Therapeutics
CARM

Delisted

CARM was delisted on the 10th of October, 2025.

Back to rankings

50 hedge funds and large institutions have $26.6M invested in Carisma Therapeutics in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 18 increasing their positions, 13 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

231% more call options, than puts

Call options by funds: $1.59M | Put options by funds: $479K

38% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 13

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.75% less ownership

Funds ownership: 23.25% → 22.5% (-0.75%)

14% less funds holding

Funds holding: 58 → 50 (-8)

33% less capital invested

Capital invested by funds: $39.6M → $26.6M (-$13M)

73% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 11

Holders
50
Holders Change
-8
Holders Change %
-13.79%
% of All Funds
0.73%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
3
Increased
18
Reduced
13
Closed
11
Calls
$1.59M
Puts
$479K
Net Calls
+$1.11M
Net Calls Change
-$557K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$410K
2
BlackRock
BlackRock
New York
+$338K
3
BCM
Bridgeway Capital Management
Texas
+$319K
4
Northern Trust
Northern Trust
Illinois
+$124K
5
Barclays
Barclays
United Kingdom
+$94.3K

Top Sellers

Rank Fund Capital Flow
1
TOTUOP
Trustees of The University of Pennsylvania
Pennsylvania
-$1.51M
2
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
-$397K
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$279K
4
Jane Street
Jane Street
New York
-$154K
5
American Century Companies
American Century Companies
Missouri
-$66.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
SG Americas Securities
26
SG Americas Securities
New York
$43K +$3.03K +1,018 +7%
AIG
27
American International Group
New York
$38.8K -$161 -54 -0.4%
Invesco
28
Invesco
Georgia
$37.3K +$7.29K +2,453 +24%
Deutsche Bank
29
Deutsche Bank
Germany
$35.9K – – –
VOYA Investment Management
30
VOYA Investment Management
Georgia
$31.7K – – –
Goldman Sachs
31
Goldman Sachs
New York
$30.8K -$6.63K -2,230 -17%
Susquehanna International Group
32
Susquehanna International Group
Pennsylvania
$29.5K +$29.9K +10,062 New
Group One Trading
33
Group One Trading
Illinois
$25.8K +$529 +178 +2%
Royal Bank of Canada
34
Royal Bank of Canada
Ontario, Canada
$25K +$11.9K +4,014 +90%
Wells Fargo
35
Wells Fargo
California
$23.9K +$3.49K +1,175 +17%
TRCT
36
Tower Research Capital (TRC)
New York
$13.5K -$18.9K -6,365 -58%
California State Teachers Retirement System (CalSTRS)
37
California State Teachers Retirement System (CalSTRS)
California
$12.9K -$4.44K -1,494 -25%
Citigroup
38
Citigroup
New York
$11.2K +$11.3K +3,802 +29,246%
AB
39
Amalgamated Bank
New York
$7K -$797 -268 -10%
New York State Common Retirement Fund
40
New York State Common Retirement Fund
New York
$6.92K -$271 -91 -4%
AIP
41
Ameritas Investment Partners
Nebraska
$6.45K – – –
Legal & General Group
42
Legal & General Group
United Kingdom
$6.32K – – –
PBK
43
Peoples Bank (Kansas)
Kansas
$732 – – –
IA
44
IFP Advisors
Florida
$603 – – –
OP
45
ORG Partners
Indiana
$586 – – –
AA
46
Ancora Advisors
Ohio
$190 – – –
National Bank of Canada
47
National Bank of Canada
Quebec, Canada
$142 – – –
Osaic Holdings
48
Osaic Holdings
Arizona
$73 – – –
SRCM
49
Signature Resources Capital Management
California
$41 +$42 +14 New
Wellington Management Group
50
Wellington Management Group
Massachusetts
– -$279K -66,041 Closed
1
2
3

CARM Hedge Fund Activity: Q4 2023 in Review

50 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q4 2023, worth a combined $26.6M — down 33% from $39.6M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of CARM and 3 opened new positions — a net loss of 8 holders — while 13 trimmed existing stakes and 18 added.

The largest buyer was Morgan Stanley, adding an estimated $410K. The largest seller was Trustees of The University of Pennsylvania, cutting an estimated $1.51M.

  • 50 institutional investors held Carisma Therapeutics (CARM) as of Q4 2023, down from 58 in Q3 2023.
  • Funds reported $26.6M of Carisma Therapeutics stock for Q4 2023, down 33% quarter-over-quarter.
  • 3 funds opened new Carisma Therapeutics positions in Q4 2023 and 11 closed out, a net change of -8 holders.
  • The largest Carisma Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $410K added.
  • The largest Carisma Therapeutics seller in Q4 2023 was Trustees of The University of Pennsylvania, an estimated $1.51M sold.

Based on aggregated 13F filings for Q4 2023.